Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

← catalyst calendar

NCT02719613

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →. With AbbVie.

Phase

Phase 2

Status

Completed

Study type

Interventional

Design

Na · None · Supportive care

Enrollment

67actual

Sites

Countries

Australia, Belgium, Canada +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2016-07-15

actual

When the study began enrolling

Primary completion

2026-02-23

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-02-23

actual

The whole study's end, after follow-up

First posted

2016-03-25

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-15

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Multiple Myeloma

Interventions

Drug: Elotuzumab — also filed as BMS-901608, HuLuc63, Empliciti
Drug: Dexamethasone
Drug: Dexamethasone
Drug: Lenalidomide — also filed as Revlimid®
Drug: Bortezomib — also filed as Velcade®
Drug: Pomalidomide — also filed as Pomalyst ®
Drug: Nivolumab — also filed as Opdivo ®

Primary outcome

what the primary-completion date above is the date OF

The number of participants who received at least one dose of elotuzumab or backbone therapy (other study drugs) and the duration of treatment will be collected.

measured Maximum duration is until all participants have discontinued study drugs, or until all participants are treated for up to 2 years, unless BMS chooses to extend the study.

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed